15 Interventions|Clear filters
Reg. name: Opdivo®
Class: PD-1 inhibitor
Adapted from Sundar R. et al. Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015 Mar; 7(2): 85-96. doi: 10.1177/175884014567470.
Opdivo® is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin Lymphoma (cHL) after Autologous Stem Cell Transplant (ASCT) and treatment with brentuximab vedotin
Reg. name: Gazyvaro®, Gazyva®
Class: Anti-CD20 monoclonal antibody
Gazyvaro® in combination with bendamustine followed by Gazyvaro® maintenance is indicated for the treatment of patients with Follicular Lymphoma (FL) who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen